RxDoctor Payments Data

Victor Guerrero, MD

Family Medicine · Buda, TXNPI 1023075074

Payments from drug & device makers

$420in general payments, 2019–2025

Across 9 payments — averaging $46.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$122
  • Johnson & Johnson$122
  • Boehringer Ingelheim$50
  • Argenx US, Inc.$37
  • Edwards Lifesciences$36
  • Nestle Healthcare Nutrition Inc.$20
  • plus $35 from 2 others

What the payments were for

  • Food & beverage$420100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$420 in reported general payments places this provider in the 45th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$70,957
Medicare patients
180
Services billed
942

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide57$78,694
TrulicityDulaglutide30$61,653
EliquisApixaban44$51,758
JardianceEmpagliflozin28$27,491
XareltoRivaroxaban12$7,258
Fluticasone-SalmeterolFluticasone Propion/Salmeterol26$4,491
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$4,028
Atorvastatin Calcium269$2,245
Duloxetine Hcl31$1,625
Losartan Potassium163$1,220
Lisinopril142$1,195
Levothyroxine Sodium114$1,062
Nano 2nd Gen Pen NeedlePen Needle, Diabetic14$1,054
Albuterol Sulfate HfaAlbuterol Sulfate48$1,043
Rosuvastatin Calcium83$1,003

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$17$61,65330 claims
Boehringer IngelheimJardiance$50$27,49128 claims
Johnson & JohnsonXarelto$122$7,25812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Buda

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →